Glenmark’s Pain Drug Fails To Meet Primary Endpoint, Path Of Another Altered By Sanofi
This article was originally published in PharmAsia News
Executive Summary
Indian drug maker Glenmark disclosed that Sanofi shelved research on one of its compounds and altered the indication of another biologic for multiple sclerosis treatment.